In what is seen as a historic move, the US Food and Drug Administration has approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness.
US biotech firm Spark Therapeutics’ (Nasdaq: ONCE) Luxturna is the first directly administered gene therapy approved in the US that targets a disease caused by mutations in a specific gene, and the decision comes well ahead of the anticipated date of mid-January 2018.
The approval was widely expected, given a unanimous recommendation vote by an FDA advisory panel in October. The company’s shares jumped as much as 6.9% to $52.39 in early trading on Tuesday following the announcement, but later fell back.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze